Testosterone use for hypoactive sexual desire disorder in postmenopausal women.
5 Repeated evidence
What this means for you: this is established.
- Type of study
- meta-analysis or systematic review
- Studied in
- people
- Participants
- not stated in the abstract
- Published
- 2023 in Menopause (New York, N.Y.)
- Cited
- 2 times by other research
- Who paid
- Not declared. PubMed carries no conflict-of-interest statement for most articles; that is not the same as independent.
- Source
- PubMed 37314872 · doi 10.1097/GME.0000000000002190
The plain-language write-up of this study is still being written.
Below is the abstract exactly as the researchers published it.
Abstract by the researchers — original text
Testosterone is an important evidence-based therapy for hypoactive sexual desire disorder (HSDD) in postmenopausal women. Clinical practice guidelines based on the most comprehensive meta-analysis of benefits and risks of testosterone therapy to date state that the sole evidence-based indication for testosterone therapy is HSDD in postmenopausal women. The guidelines also provide recommendations regarding identification of patients, dosing, monitoring, and follow-up. This Practice Pearl will discuss evidence-based testosterone therapy for management of HSDD in postmenopausal women.